A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

This study tests a combination of three cancer drugs — nivolumab, ipilimumab, and cabozantinib — for patients with kidney cancer (renal cell carcinoma) that has spread to the brain. These drugs work by boosting the immune system and blocking tumor growth signals. **You may be eligible if...** - You are 18 or older with confirmed kidney cancer spread to the brain - Your brain metastases have not yet been treated, or have grown after local treatment like radiosurgery - You do not need steroids to manage brain symptoms (or only have mild symptoms) - You have not previously received anti-CTLA-4 therapy, cabozantinib, or MET inhibitors - You are in reasonably good health **You may NOT be eligible if...** - You have rapidly worsening brain symptoms requiring urgent treatment - You have received the specific drugs being tested before - You have severe other illnesses that would prevent safe participation - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.